NCT05932550

Safety of Maraviroc for Post-stroke Depression

Safety of Maraviroc for Post-stroke Depression (Proof-of-concept)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Tel-Aviv Sourasky Medical Center · Other Government
• Sex: All
• Age: 50 Years – 86 Years
• Healthy volunteers: Not accepted

Summary

Post-stroke depression (PSD) is a barrier to effective rehabilitation and recovery after stroke. Current treatment options are limited and there is an unmet need for specific and effective therapeutic options. Objective: To examine the safety and efficacy of Maraviroc, a CCR5 antagonist, as a possible add-on treatment option for PSD, in an open-labeled proof-of-concept clinical trial. Design, Setting, and Participants: A 10-week trial of daily oral 300 mg Maraviroc in ten patients with subcortical stroke suffering from PSD. Follow-up: eight weeks after completing treatment. Main Outcome Measure: A change in the Montgomery-Asberg Depression Rating Scale (MADRS).

Conditions

• Post-stroke Depression

Interventions

Type	Name	Description
DRUG	Maraviroc 300 mg	10 week treatment as add-on therapy to anti-depressants

Timeline

• Start date: 2020-08-04
• Primary completion: 2022-08-04
• Completion: 2022-08-04
• First posted: 2023-07-06
• Last updated: 2023-07-06

Locations

1 site across 1 country: Israel